{
  "id": 7402405,
  "title": "ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate",
  "url": "https://urgent.news/2026/09/14/ros1-targeting-lung-cancer-drug-yields-90-response-rate",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-14T20:26:40.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/iaslc/122999"
  },
  "original_language": "en",
  "account": "A groundbreaking lung cancer medication targeting ROS1 has demonstrated a remarkable 90% response rate in patients who had never been treated with a tyrosine kinase inhibitor (TKI), according to updated findings from a phase I/II trial. Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center, presenting at the World Conference on Lung Cancer in Seoul, reported a 94% objective response rate over a median follow-up of 15.2 months. The response persisted for at least 6, 9, and 12 months in 96%, 94%, and 86% of patients, respectively, with no median progression observed at these intervals. Among 10 patients with CNS involvement, all exhibited an intracranial response, with 100% achieving a complete response. No CNS progression occurred among patients without pre-existing brain metastases, underscoring the drug's efficacy in this critical area. Dr. Drilon emphasized that these results support the consideration of zidesamtinib as a frontline therapy for TKI-naive patients, potentially paving the way for a supplemental FDA application to expand its use in the first line of treatment.",
  "summary": "(MedPage Today) -- Most patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI) had an objective response with zidesamtinib (Jideytro), according to...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}